Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

PURPOSE: Afatinib, an oral irreversible ErbB family blocker, undergoes minimal metabolism by non-enzyme-catalysed adduct formation with proteins or nucleophilic small molecules and is predominantly non-renally excreted via the entero-hepatic system. This trial assessed whether mild or moderate hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnell, David, Buschke, Susanne, Fuchs, Holger, Gansser, Dietmar, Goeldner, Rainer-Georg, Uttenreuther-Fischer, Martina, Stopfer, Peter, Wind, Sven, Petersen-Sylla, Marc, Halabi, Atef, Koenen, Rüdiger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112049/
https://www.ncbi.nlm.nih.gov/pubmed/24906422
http://dx.doi.org/10.1007/s00280-014-2484-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112049/
https://www.ncbi.nlm.nih.gov/pubmed/24906422
http://dx.doi.org/10.1007/s00280-014-2484-y

Ejemplares similares